PubMed · 4004369
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
C H Moens, D Moens, P H Moens. 1985. Bufexamac crystals in synovial fluid analysis.. https://doi.org/10.1136/ard.44.5.357-b
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Bufexamac is an anti-inflammatory agent used as topical treatment of various pruritic diseases. Since it was put on the market, this product has been blamed for the occurrence of contact dermatitis (eczema, urticaria) and, rarely, severe toxicodermia. We report a case of severe contact dermatitis developed after application of bufexamac (Parfenac) cream. Patch-tests performed two months after the acute phase were positive (+ + +) for both Parfenac cream and bufexamac.
447 children between 0 and 24 months with diaper dermatitis were treated by topical application of Parfenac-Fettsalbe (Bufexamac). This panel was selected out of 844 patients which were originally in the protocol. The Parfenac-Fettsalbe was well tolerated, 7 children presented local side effects. 62.71% of treated girls showed very good results, whereas 59.89% of boys showed this outcome. Good results were obtained in 24.35% of girls and 21.93% of boys. Very good (no efflorescences remaining) and good results (some remaining efflorescences) were thus found in more than 80% of patients treated: with respect to corticosteroid advoidance this can be regarded as an effective antiphlogistic medication for diaper dermatitis. Non responders might have been superinfected with microorganisms as candida and staphylococci. In addition, epidemiological considerations are reported in that study.
12 patients suffering from hemorrhoidal complaints were treated with hemorrhoidal suppositories containing Proctoparf-bufexamac. Using the HPCL method, we measured the concentrations of bufexamac in the serum after 30, 45 and 60 minutes as well as after 2, 3, 6, 7.5 and 20 hours. Neither bufexamac nor its major metabolite (4-butoxyphenyl acetic acid) could be detected in concentrations above 0.2 micrograms/ml and 0.5 micrograms/ml, respectively. These results prove that the application of Proctoparf suppositories is not associated with any significant systemic absorption of bufexamac.